drug approval – Discover Pharma

Welcome to Discover Pharma! Today is : March 16, 2026

drug approval

Biologics & Biosimilars,Biomanufacturing,Biotech,Clinical Development,Clinical Trials,Drug approval,Drug Development,FDA,Rare Diseases,Research & Development
Hansa Biopharma’s BLA for imlifidase accepted by FDA
Hansa Biopharma’s Biologics License Application (BLA) for imlifidase has been [...]

February 19, 2026
Biologics & Biosimilars,Clinical Development,Patient Centricity,Regulatory Affairs
NICE recommends Mirikizumab for moderately to severely active Crohn’s Disease after biologic failure
Mirikizumab is now recommended by NICE for routine NHS use [...]

July 14, 2025
Artificial Intelligence,Biologics & Biosimilars,Clinical Trials,Regulatory Affairs
FDA shifts drug testing paradigm with plan to replace animal studies in monoclonal antibody development
Regulators back AI and organ-on-a-chip technologies to modernize safety evaluation [...]

June 24, 2025
Clinical Trials,Drug Development,Patient Centricity,Regulatory Affairs
NICE backs mirikizumab for treatment-resistant Crohn’s disease
The National Institute for Health and Care Excellence (NICE) has [...]

May 30, 2025
Drug Delivery & Formulation,Regulatory Affairs
FDA approves Khindivi oral solution for pediatric adrenal insufficiency
Eton Pharmaceuticals has received US regulatory approval for Khindivi, the [...]

May 29, 2025

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK